Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo

Eijiro Jimi, Kazuhiro Aoki, Hiroaki Saito, Fulvio D'Acquisto, Michael J. May, Ichiro Nakamura, Testuo Sudo, Takefumi Kojima, Fujio Okamoto, Hidefumi Fukushima, Koji Okabe, Keiichi Ohya, Sankar Ghosh

Research output: Contribution to journalArticle

365 Citations (Scopus)

Abstract

Bone destruction is a pathological hallmark of several chronic inflammatory diseases, including rheumatoid arthritis and periodontitis. Inflammation-induced bone loss of this sort results from elevated numbers of bone-resorbing osteoclasts. Gene targeting studies have shown that the transcription factor nuclear factor-κB (NF-κB) has a crucial role in osteoclast differentiation, and blocking NF-κB is a potential strategy for preventing inflammatory bone resorption. We tested this approach using a cell-permeable peptide inhibitor of the IκB-kinase complex, a crucial component of signal transduction pathways to NF-κB. The peptide inhibited RANKL-stimulated NF-κB activation and osteoclastogenesis both in vitro and in vivo. In addition, this peptide significantly reduced the severity of collagen-induced arthritis in mice by reducing levels of tumor necrosis factor-α and interleukin-1β, abrogating joint swelling and reducing destruction of bone and cartilage. Therefore, selective inhibition of NF-κB activation offers an effective therapeutic approach for inhibiting chronic inflammatory diseases involving bone resorption.

Original languageEnglish
Pages (from-to)617-624
Number of pages8
JournalNature medicine
Volume10
Issue number6
DOIs
Publication statusPublished - Jun 1 2004
Externally publishedYes

Fingerprint

Osteogenesis
Bone
Osteoclasts
Bone Resorption
Bone and Bones
Chronic Disease
Osteitis
Peptides
Experimental Arthritis
Gene Targeting
Periodontitis
Interleukin-1
Cartilage
Signal Transduction
Rheumatoid Arthritis
Transcription Factors
Phosphotransferases
Tumor Necrosis Factor-alpha
Joints
Chemical activation

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Jimi, E., Aoki, K., Saito, H., D'Acquisto, F., May, M. J., Nakamura, I., ... Ghosh, S. (2004). Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nature medicine, 10(6), 617-624. https://doi.org/10.1038/nm1054

Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. / Jimi, Eijiro; Aoki, Kazuhiro; Saito, Hiroaki; D'Acquisto, Fulvio; May, Michael J.; Nakamura, Ichiro; Sudo, Testuo; Kojima, Takefumi; Okamoto, Fujio; Fukushima, Hidefumi; Okabe, Koji; Ohya, Keiichi; Ghosh, Sankar.

In: Nature medicine, Vol. 10, No. 6, 01.06.2004, p. 617-624.

Research output: Contribution to journalArticle

Jimi, E, Aoki, K, Saito, H, D'Acquisto, F, May, MJ, Nakamura, I, Sudo, T, Kojima, T, Okamoto, F, Fukushima, H, Okabe, K, Ohya, K & Ghosh, S 2004, 'Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo', Nature medicine, vol. 10, no. 6, pp. 617-624. https://doi.org/10.1038/nm1054
Jimi, Eijiro ; Aoki, Kazuhiro ; Saito, Hiroaki ; D'Acquisto, Fulvio ; May, Michael J. ; Nakamura, Ichiro ; Sudo, Testuo ; Kojima, Takefumi ; Okamoto, Fujio ; Fukushima, Hidefumi ; Okabe, Koji ; Ohya, Keiichi ; Ghosh, Sankar. / Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. In: Nature medicine. 2004 ; Vol. 10, No. 6. pp. 617-624.
@article{ec05e843e2cb401a889841fb6b3f56e6,
title = "Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo",
abstract = "Bone destruction is a pathological hallmark of several chronic inflammatory diseases, including rheumatoid arthritis and periodontitis. Inflammation-induced bone loss of this sort results from elevated numbers of bone-resorbing osteoclasts. Gene targeting studies have shown that the transcription factor nuclear factor-κB (NF-κB) has a crucial role in osteoclast differentiation, and blocking NF-κB is a potential strategy for preventing inflammatory bone resorption. We tested this approach using a cell-permeable peptide inhibitor of the IκB-kinase complex, a crucial component of signal transduction pathways to NF-κB. The peptide inhibited RANKL-stimulated NF-κB activation and osteoclastogenesis both in vitro and in vivo. In addition, this peptide significantly reduced the severity of collagen-induced arthritis in mice by reducing levels of tumor necrosis factor-α and interleukin-1β, abrogating joint swelling and reducing destruction of bone and cartilage. Therefore, selective inhibition of NF-κB activation offers an effective therapeutic approach for inhibiting chronic inflammatory diseases involving bone resorption.",
author = "Eijiro Jimi and Kazuhiro Aoki and Hiroaki Saito and Fulvio D'Acquisto and May, {Michael J.} and Ichiro Nakamura and Testuo Sudo and Takefumi Kojima and Fujio Okamoto and Hidefumi Fukushima and Koji Okabe and Keiichi Ohya and Sankar Ghosh",
year = "2004",
month = "6",
day = "1",
doi = "10.1038/nm1054",
language = "English",
volume = "10",
pages = "617--624",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo

AU - Jimi, Eijiro

AU - Aoki, Kazuhiro

AU - Saito, Hiroaki

AU - D'Acquisto, Fulvio

AU - May, Michael J.

AU - Nakamura, Ichiro

AU - Sudo, Testuo

AU - Kojima, Takefumi

AU - Okamoto, Fujio

AU - Fukushima, Hidefumi

AU - Okabe, Koji

AU - Ohya, Keiichi

AU - Ghosh, Sankar

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Bone destruction is a pathological hallmark of several chronic inflammatory diseases, including rheumatoid arthritis and periodontitis. Inflammation-induced bone loss of this sort results from elevated numbers of bone-resorbing osteoclasts. Gene targeting studies have shown that the transcription factor nuclear factor-κB (NF-κB) has a crucial role in osteoclast differentiation, and blocking NF-κB is a potential strategy for preventing inflammatory bone resorption. We tested this approach using a cell-permeable peptide inhibitor of the IκB-kinase complex, a crucial component of signal transduction pathways to NF-κB. The peptide inhibited RANKL-stimulated NF-κB activation and osteoclastogenesis both in vitro and in vivo. In addition, this peptide significantly reduced the severity of collagen-induced arthritis in mice by reducing levels of tumor necrosis factor-α and interleukin-1β, abrogating joint swelling and reducing destruction of bone and cartilage. Therefore, selective inhibition of NF-κB activation offers an effective therapeutic approach for inhibiting chronic inflammatory diseases involving bone resorption.

AB - Bone destruction is a pathological hallmark of several chronic inflammatory diseases, including rheumatoid arthritis and periodontitis. Inflammation-induced bone loss of this sort results from elevated numbers of bone-resorbing osteoclasts. Gene targeting studies have shown that the transcription factor nuclear factor-κB (NF-κB) has a crucial role in osteoclast differentiation, and blocking NF-κB is a potential strategy for preventing inflammatory bone resorption. We tested this approach using a cell-permeable peptide inhibitor of the IκB-kinase complex, a crucial component of signal transduction pathways to NF-κB. The peptide inhibited RANKL-stimulated NF-κB activation and osteoclastogenesis both in vitro and in vivo. In addition, this peptide significantly reduced the severity of collagen-induced arthritis in mice by reducing levels of tumor necrosis factor-α and interleukin-1β, abrogating joint swelling and reducing destruction of bone and cartilage. Therefore, selective inhibition of NF-κB activation offers an effective therapeutic approach for inhibiting chronic inflammatory diseases involving bone resorption.

UR - http://www.scopus.com/inward/record.url?scp=2942703810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942703810&partnerID=8YFLogxK

U2 - 10.1038/nm1054

DO - 10.1038/nm1054

M3 - Article

VL - 10

SP - 617

EP - 624

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 6

ER -